VKH
AKBA icon

Virtu KCG Holdings’s Akebia Therapeutics AKBA Stock Holding History

Virtu KCG Holdings’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$607K Buy
+42,223
New +$535K 0.02% 967
2017
Q1 		– Sell
-31,740
Closed -$330K – 3086
2016
Q4 		$330K Buy
+31,740
New +$273K 0.01% 1973
2015
Q3 		– Sell
-11,299
Closed -$116K – 3298
2015
Q2 		$116K Buy
+11,299
New +$96.4K ﹤0.01% 2854

Other funds holding AKBA

EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Virtu KCG Holdings's AKBA Position: Q2 2017 in Review

Virtu KCG Holdings opened a new position in Akebia Therapeutics (AKBA) in Q2 2017: 42,223 shares worth $607K. The stake represents 0.02% of the portfolio and ranks #967 among its holdings. This is a return to the name: Virtu KCG Holdings previously reported a position in AKBA as recently as Q4 2016.

Virtu KCG Holdings first reported a position in AKBA in Q2 2015 and has held it in 3 quarters since. 119 funds tracked by Wall St. Rank hold AKBA as of Q2 2017.

  • Virtu KCG Holdings held 42,223 shares of Akebia Therapeutics worth $607K as of Q2 2017.
  • Akebia Therapeutics was a new Virtu KCG Holdings position in Q2 2017.
  • Akebia Therapeutics made up 0.02% of Virtu KCG Holdings's portfolio in Q2 2017, its #967 holding.
  • Virtu KCG Holdings first reported a position in Akebia Therapeutics in Q2 2015 and has held it in 3 quarters since.
  • 119 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.